If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
Marker for brain-tumor diagnosis (Astrocytoma, Oligidendroglioma), CE IVD. Antibody clone H09 reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sections from formalin-fixed brain tumor specimens. Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. The high frequency and distribution of the IDH1 R132H mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma WHO grade II from pilocytic astrocytoma or ependymoma. Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis. This antibody is highly useful for tumor classification and in detecting single infiltrating tumor cells.
Monoclonal antibody specific for IDH1 H132R mutation.Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Acta Neuropathol. 118(5): 599-601, 2009. / Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A.Brain Pathol. 20(1): 245-254, 2010. / Application of mutant IDH1 anti-body to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. Am J Surg Pathol. 34(8):1199-1204, 2010.